This preprint is under consideration at Annals of Clinical Microbiology and Antimicrobials. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Miguel Alejandro Pinzón
Clinica Medellin
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: To date, there is no specific antiviral therapy for severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) that causes Coronavirus disease 2019 (Covid-19). Since there is no specific therapy against SARS-CoV2, current efforts aim to prevent contagion through public health measures and develop a protective vaccine. While waiting for the latter, it is necessary to evaluate the drugs that at least, in initial studies, suggested some degree of utility in the management of Covid-19 or its complications.
The Objective of the study was to describe the clinical manifestations and outcomes of patients with severe Covid-19 Pneumonia treated with corticosteroids and colchicine.
Materials and Methods: A cross sectional study of 301 adult patients with Covid-19 Pneumonia confirmed by Real-Time Polymerase Chain Reaction for SARS-CoV2 (RT-PCR SARS-CoV2), Berlin protocol, who required hospitalization in three hospitals in Antioquia, Colombia. Patients were treated according to the institutional protocol (from March 20, 2020 to June 30, 2020) with corticosteroid if the patient required supplemental oxygen. From July 1, 2020, the management protocol changed with the addition of colchicine to all patients admitted to the institutions. The treatment was supervised and monitored by the same specialist in infectology of the institutions.
We describe the clinical manifestations and outcomes of the patients who received these treatments. The patient’s information was analyzed according to the outcome of interest (alive/dead) with univariate, bivariate, and multivariate measures to adjust the variables that presented statistical association.
Results: All patients had pneumonia documented by chest computed tomography with ground glass images and presented an alveolar pressure / inspired oxygen fraction (PaFi) less than 300. 240 (79.7%) of patients received corticosteroids, and 145 (48.2%) also received colchicine; of these, 14 (9.6%) died vs. 23 (14.7%) of those who did not receive it. Hospital mortality due to severe Covid-19 Pneumonia was 12.3% in three hospitals in Colombia.
Conclusions: Treatment with corticosteroids and colchicine for managing patients with severe Covid-19 pneumonia was associated with low mortality at the hospital level. Randomized, placebo-controlled studies are required to evaluate the effect of corticosteroids and colchicine on complications or death from Covid-19.
Keywords
Coronavirus, COVID-19, Colchicine, Corticosteroids, Pneumonia
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version (no preprint)
Posted 22 Jun, 2021
Editor assigned
On 22 Jun, 2021
Submission checks complete
On 22 Jun, 2021
Editor invited
On 22 Jun, 2021
First submitted
On 22 Jun, 2021
Editorial decision: Minor revision
On 02 Feb, 2021
This version was not preprinted
Version (no preprint)
Posted 01 Jun, 2021
Editorial decision: Minor revision
On 01 Jun, 2021
Review #1 received
Received 22 May, 2021
Reviews received
Received 21 May, 2021
Reviewers invited
Invitations sent on 21 May, 2021
Editor assigned
On 21 May, 2021
Reviewer #1 agreed
On 20 May, 2021
Submission checks complete
On 20 May, 2021
Editor invited
On 20 May, 2021
First submitted
On 20 May, 2021
This version was not preprinted
Version (no preprint)
Posted 30 Apr, 2021
Editorial decision: Major revision
On 30 Apr, 2021
Review #1 received
Received 11 Apr, 2021
Reviewers invited
Invitations sent on 09 Apr, 2021
Reviewer #1 agreed
On 09 Apr, 2021
Editor assigned
On 21 Feb, 2021
Submission checks complete
On 21 Feb, 2021
Editor invited
On 21 Feb, 2021
This version was not preprinted
Version 1
Posted 23 Oct, 2020
No community comments so far
Editorial decision: Major revision
On 01 Feb, 2021
Review #2 received
Received 22 Jan, 2021
Review #1 received
Received 22 Jan, 2021
Reviewer #5 agreed
On 20 Jan, 2021
Reviewer #4 agreed
On 19 Jan, 2021
Reviewer #3 agreed
On 18 Jan, 2021
Reviewer #2 agreed
On 17 Jan, 2021
Reviewer #1 agreed
On 17 Jan, 2021
Reviewers invited
Invitations sent on 26 Oct, 2020
Editor assigned
On 20 Oct, 2020
Editor invited
On 19 Oct, 2020
Submission checks complete
On 19 Oct, 2020
First submitted
On 17 Oct, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
General Microbiology
Learn more about our company.
This preprint is under consideration at Annals of Clinical Microbiology and Antimicrobials. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Miguel Alejandro Pinzón
Clinica Medellin
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version (no preprint)
Posted 22 Jun, 2021
Editor assigned
On 22 Jun, 2021
Submission checks complete
On 22 Jun, 2021
Editor invited
On 22 Jun, 2021
First submitted
On 22 Jun, 2021
Editorial decision: Minor revision
On 02 Feb, 2021
This version was not preprinted
Version (no preprint)
Posted 01 Jun, 2021
Editorial decision: Minor revision
On 01 Jun, 2021
Review #1 received
Received 22 May, 2021
Reviews received
Received 21 May, 2021
Reviewers invited
Invitations sent on 21 May, 2021
Editor assigned
On 21 May, 2021
Reviewer #1 agreed
On 20 May, 2021
Submission checks complete
On 20 May, 2021
Editor invited
On 20 May, 2021
First submitted
On 20 May, 2021
This version was not preprinted
Version (no preprint)
Posted 30 Apr, 2021
Editorial decision: Major revision
On 30 Apr, 2021
Review #1 received
Received 11 Apr, 2021
Reviewers invited
Invitations sent on 09 Apr, 2021
Reviewer #1 agreed
On 09 Apr, 2021
Editor assigned
On 21 Feb, 2021
Submission checks complete
On 21 Feb, 2021
Editor invited
On 21 Feb, 2021
This version was not preprinted
Version 1
Posted 23 Oct, 2020
No community comments so far
Editorial decision: Major revision
On 01 Feb, 2021
Review #2 received
Received 22 Jan, 2021
Review #1 received
Received 22 Jan, 2021
Reviewer #5 agreed
On 20 Jan, 2021
Reviewer #4 agreed
On 19 Jan, 2021
Reviewer #3 agreed
On 18 Jan, 2021
Reviewer #2 agreed
On 17 Jan, 2021
Reviewer #1 agreed
On 17 Jan, 2021
Reviewers invited
Invitations sent on 26 Oct, 2020
Editor assigned
On 20 Oct, 2020
Editor invited
On 19 Oct, 2020
Submission checks complete
On 19 Oct, 2020
First submitted
On 17 Oct, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
General Microbiology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: To date, there is no specific antiviral therapy for severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) that causes Coronavirus disease 2019 (Covid-19). Since there is no specific therapy against SARS-CoV2, current efforts aim to prevent contagion through public health measures and develop a protective vaccine. While waiting for the latter, it is necessary to evaluate the drugs that at least, in initial studies, suggested some degree of utility in the management of Covid-19 or its complications.
The Objective of the study was to describe the clinical manifestations and outcomes of patients with severe Covid-19 Pneumonia treated with corticosteroids and colchicine.
Materials and Methods: A cross sectional study of 301 adult patients with Covid-19 Pneumonia confirmed by Real-Time Polymerase Chain Reaction for SARS-CoV2 (RT-PCR SARS-CoV2), Berlin protocol, who required hospitalization in three hospitals in Antioquia, Colombia. Patients were treated according to the institutional protocol (from March 20, 2020 to June 30, 2020) with corticosteroid if the patient required supplemental oxygen. From July 1, 2020, the management protocol changed with the addition of colchicine to all patients admitted to the institutions. The treatment was supervised and monitored by the same specialist in infectology of the institutions.
We describe the clinical manifestations and outcomes of the patients who received these treatments. The patient’s information was analyzed according to the outcome of interest (alive/dead) with univariate, bivariate, and multivariate measures to adjust the variables that presented statistical association.
Results: All patients had pneumonia documented by chest computed tomography with ground glass images and presented an alveolar pressure / inspired oxygen fraction (PaFi) less than 300. 240 (79.7%) of patients received corticosteroids, and 145 (48.2%) also received colchicine; of these, 14 (9.6%) died vs. 23 (14.7%) of those who did not receive it. Hospital mortality due to severe Covid-19 Pneumonia was 12.3% in three hospitals in Colombia.
Conclusions: Treatment with corticosteroids and colchicine for managing patients with severe Covid-19 pneumonia was associated with low mortality at the hospital level. Randomized, placebo-controlled studies are required to evaluate the effect of corticosteroids and colchicine on complications or death from Covid-19.
Figure 1
Loading...